MedTrace Logo

Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization

NCT00508742 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1866

Last updated 2013-05-10

Study results available
· View outcomes & findings →

Summary

This study is designed to assess the impact of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) on nasopharyngeal colonization with Streptococcus pneumoniae in healthy infants.

Conditions

  • Pneumococcal Infections

Interventions

BIOLOGICAL

13-valent Pneumococcal Conjugate Vaccine

1 dose at 2, 4, 6 and 12 months of age

BIOLOGICAL

7 valent pneumococcal conjugate vaccine

1 dose at 2, 4, 6 and 12 months of age

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
42 Days
Max Age
98 Days
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00508742 on ClinicalTrials.gov